{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-26-000033","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.132108+00:00","generated_at":"2026-05-15T14:54:32.313743+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s","bullets":["Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.","Will no longer advertise compounded GLP-1s; limited compounding only for clinical necessity.","Novo Nordisk dismisses its lawsuit against Hims & Hers without prejudice.","Existing patients can transition to FDA-approved GLP-1s when clinically appropriate.","CEO Dudum: partnership enables scaled distribution of innovations for affordable access."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-26-000033","json":"https://secwatch.observer/filing/0001773751-26-000033.json","markdown":"https://secwatch.observer/filing/0001773751-26-000033.md","text":"https://secwatch.observer/filing/0001773751-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375126000033/0001773751-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375126000033/hims-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:54:32.313743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}